UK markets open in 13 minutes

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.9500+0.0250 (+2.70%)
At close: 03:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.9250
Open0.9500
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.9000 - 0.9500
52-week range0.3900 - 18.0000
Volume2,262
Avg. volume3,511
Market cap4.505M
Beta (5Y monthly)3.56
PE ratio (TTM)N/A
EPS (TTM)-1.4000
Earnings date20 May 2024 - 24 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)

    A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical PosterFRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Sp

  • GlobeNewswire

    Arch Therapeutics Provides Year End Operational Update

    Continued Strong Trends in Orders and Paid ClaimsFRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”). During its fourth fiscal quarter, the Company

  • GlobeNewswire

    Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)

    AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg UlcersFRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanc